Yan Leyfman: When is Risk-Reducing Mastectomy (RRM) Cost-Effective?
Yan Leyfman, Medical Correspondent at OncLive, shared on X about a recent paper by Xia Wei et al., published in JAMA Oncology.
“When is risk-reducing mastectomy (RRM) cost-effective?
New economic modeling suggests that RRM is cost-effective for UK women aged 30–55 with a ≥35% lifetime breast cancer (BC) risk — even without BRCA1/2/PALB2 mutations.
Compared with risk-stratified screening plus medical prevention (tamoxifen or anastrozole), RRM at this threshold:
- Falls below UK’s cost-effectiveness threshold (£20K–£30K/QALY)
- Could prevent ~11% of annual BC cases
- Shows strong probability of cost-effectiveness in sensitivity analyses
Implication: Guidelines may need to broaden RRM eligibility beyond traditional mutation carriers to include women with ≥35% lifetime risk.”
Title: Defining Lifetime Risk Thresholds for Breast Cancer Surgical Prevention
Authors: Xia Wei, Lea Mansour, Samuel Oxley, Caitlin T. Fierheller, Ashwin Kalra, Jacqueline Sia, Subhasheenee Ganesan, Michail Sideris, Li Sun, Adam Brentnall, Stephen Duffy, D. Gareth Evans, Li Yang, Rosa Legood, Ranjit Manchanda
Read The Full Article at JAMA Oncology.
More posts featuring Yan Leyfman.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023